Boston Scientific Corporation BSX, despite industrywide macroeconomic upheavals, has been seeing strong growth momentum ...

StockNews.com downgraded shares of Boston Scientific (NYSE:BSX – Free Report) from a buy rating to a hold rating in a research note issued to investors on Thursday. Other analysts have also issued ...

So far, BSX stock has risen 19% year-to-date. Separately, CROX reports earnings tomorrow. Will the stock pop on the news? See ...

Nations Financial Group Inc. IA ADV trimmed its holdings in Boston Scientific Co. (NYSE:BSX – Free Report) by 5.9% in the ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

The favorable estimate revisions indicate brokers’ confidence in the stock. As of Feb. 20, 2025, Boston Scientific's stock is trading at $105.67, reflecting a year-to-date increase of 18.9%.

Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions at Boston Scientific Corp (NYSE:BSX), ...

John Bradley Sorenson, Executive Vice President of Global Operations at Boston Scientific Corp (NYSE:BSX), recently reported several transactions involving the company's common stock. The ...